logo
Retinol May Thin Your Skin, but That's Why It Works

Retinol May Thin Your Skin, but That's Why It Works

New York Times18-07-2025
Retinoids initially thin out the very top layer of the epidermis (called the stratum corneum). NYT Wirecutter
Skin is made of several layers: From the outside in, they're the epidermis, the dermis, and the hypodermis or subcutaneous fat. The outermost layer, the epidermis, is itself composed of several stacked components. Sitting on the very outside of that top layer is the stratum corneum — and when we talk about 'thinning out the skin,' this is the layer we're talking about.
By the time the cells reach this layer, they've lost their nucleus and are essentially dead, said dermatologist Muneeb Shah. So having a 'thick' stratum corneum isn't always a good thing, as the buildup of dead skin cells can make the skin appear dull. Your skin sheds the dead cells on its own, but using a retinoid (or exfoliant) speeds up the shedding of that dead layer to reveal newer, brighter skin.
So yes, a retinoid thins out this topmost layer initially — but that's a good thing. 'This can be beneficial because it can improve skin texture and tone, reduce clogged pores and acne, and allow other ingredients to penetrate more effectively,' said dermatologist Chelsea Hoffman.
This thinning is temporary because by about four weeks of consistent retinoid use, the fibroblasts in the dermis are producing more collagen and elastin, ultimately thickening the dermis and skin overall, said dermatologist Fatima Fahs. However, that very top layer of dead skin cells 'remains thinner than it would be without retinoid use,' Fahs said, because skin cells are in a constant state of turnover. So whether the thinning is temporary depends on how you look at it, but the good news is, this thinning is working to reveal brighter, smoother skin, Fahs said.
This initial thinning can contribute to 'retinization' — the irritation, skin flaking, breakouts, and redness that crop up for some people when they start to use retinoids. Folks online sometimes refer to it as the 'retinol uglies' or 'purging.' Rest assured that these are normal and temporary side effects for most people (because skin often builds up a tolerance to retinoids after six to eight weeks), and using face moisturizer may help to alleviate some of them. Part of the reaction, such as flaking, can be attributed to those dead skin cells shedding at a quicker rate.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Could This Psychedelic Drug Stock Be a Top Buy for 2026?
Could This Psychedelic Drug Stock Be a Top Buy for 2026?

Yahoo

time10 minutes ago

  • Yahoo

Could This Psychedelic Drug Stock Be a Top Buy for 2026?

Amid a global mental health crisis, the demand for new and effective treatment options is on the rise, particularly in the realm of psychedelic-assisted therapies. Experts believe the psychedelic drug market will grow from $4.1 billion in 2025 to an impressive $7.8 billion by 2030, reflecting a steady compound annual growth rate (CAGR) of 13.7%. As the space gains traction, one small biotech company has caught some investors' attention: Mind Medicine (MNMD), also known as MindMed for short. In its most recent earnings update, MindMed reported solid progress with enrollment across three pivotal Phase 3 trials for its lead candidate, MM120, a refined version of recreational drug lysergide d-tartrate (LSD) currently being studied for generalized anxiety disorder (GAD) and major depressive disorder (MDD). More News from Barchart Supermicro's Earnings Selloff Explained: Should You Buy SMCI Stock Now? Amazon's $36M Bet on Quantum Computing: What Investors Need to Know AMD Stock Slips After Q2 Earnings, But Here's Why It's a Buying Opportunity Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Topline data from these trials is expected in 2026, setting the stage for a potential commercial launch by 2028. And analysts are also beginning to take notice. Oppenheimer, for example, recently expressed optimism based on what it believes could be 'powerful' Phase 3 data next year. So, with clinical milestones approaching, would it be wise to buy the shares of this psychedelic drugmaker? About Mind Medicine Stock MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Its most advanced program, MM120, is currently in Phase 3 trials for GAD. Another key candidate, MM402, an MDMA-related compound, is in Phase 1 trials and being studied for its potential to address core symptoms of autism spectrum disorder (ASD). With a pipeline focused on conditions that often lack effective long-term solutions, the company is aiming to bring a fresh approach to mental health treatment. Valued at roughly $747 million by market capitalization, shares of this psychedelic therapy-focused company are gaining traction as investors take note of its advancing clinical pipeline and growing role in mental health innovation. Over the past year, shares have risen 34%, and the rally has only intensified in 2025 with a year-to-date (YTD) gain of 41%. That easily tops the broader S&P 500 Index's ($SPX) 22% gain over the past year and its 8% rise so far this year. Most notably, MindMed has surged 49% in just the last three months, highlighting growing investor interest. A Look Inside Mind Medicine's Q2 Earnings MindMed's fiscal 2025 second-quarter earnings, released on July 31, painted a mixed picture as the company deepens its push into late-stage development. The pre-revenue biotech firm posted a loss of $0.50 per share, widening from a loss of $0.26 a year ago and missing Wall Street's forecast of a $0.38 loss per share. The shortfall was driven by a sharp increase in research and development expenses, which surged 103.5% year-over-year (YOY) to $29.8 million, primarily due to the advancement of the MM120 program. While the company is investing heavily in advancing the MM120 program, one area of concern is the limited insight into the treatment's long-term effectiveness. So far, Phase 2 data only tracks results up to 12 weeks, leaving questions about how durable the benefits may be over an extended period. That said, MindMed's financial position remains strong. As of June 30, the company reported $237.9 million in cash, cash equivalents, and investments, enough to support operations into 2027 and beyond the first topline readout from its Phase 3 MM120 ODT trial. Meanwhile, clinical progress continues to move forward. MindMed remains on schedule with enrollment across three pivotal Phase 3 trials — Voyage, Panorama, and Emerge — which are focused on MM120 ODT for the treatment of GAD and MDD. These studies are designed to assess the efficacy of MM120 ODT as a standalone treatment, without the need for psychotherapy. The company expects topline data from its Phase 3 Voyage trial in the first half of 2026, followed by Panorama and Emerge in the second half. What Do Analysts Think About Mind Medicine Stock While investors' reaction to the company's Q2 results was somewhat underwhelming, sentiment took a sharp positive turn on Aug. 4 when shares jumped nearly 11% following an upgrade from Oppenheimer. Analyst Jay Olson lifted the psychedelic drug developer to an 'Outperform' rating and set a 12- to 18-month price target of $25, citing the promising potential of its lead candidate, MM120. Olson highlighted MM120's 'unique clinical profile,' describing it as a pharmaceutical form of LSD that delivers a less intense but longer-lasting psychedelic experience compared to other approaches. The analyst also emphasized the drug's potential in treating neuropsychiatric conditions like GAD and MDD. Backing his optimism, Olson noted encouraging Phase 2 trial data for MM120 in GAD, which showed favorable remission rates as well as a favorable safety and tolerability profile over a 12-week period. In his view, MindMed remains undervalued and is strategically positioned ahead of its anticipated Phase 3 readout Overall, MNMD stock has earned a resounding vote of confidence on Wall Street, carrying a consensus rating of 'Strong Buy.' Of the 11 analysts covering the stock, a majority of 10 analysts recommend a "Strong Buy" while the remaining one gives a 'Moderate Buy' rating. The average analyst price target of $25 indicates significant upside potential of 157% from the current price levels. Final Thoughts While MindMed's journey comes with the usual biotech risks — especially given its pre-revenue status, rising R&D costs, and questions around the long-term durability of MM120's effects — the company's progress in late-stage trials, strong financial position, and growing confidence from Wall Street paint an encouraging picture. For investors comfortable with biotech volatility and looking to gain exposure to the emerging psychedelic therapy space, MindMed could be a promising buy ahead of its anticipated Phase 3 milestones in 2026. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

2025 Cat Food Innovation of the Year Award Goes To Natural Balance® Ultra Protein
2025 Cat Food Innovation of the Year Award Goes To Natural Balance® Ultra Protein

Yahoo

time10 minutes ago

  • Yahoo

2025 Cat Food Innovation of the Year Award Goes To Natural Balance® Ultra Protein

New Ultra Protein formulas feature nutrient-rich organs for high protein levels & premium taste BROWNWOOD, Texas, Aug. 7, 2025 /PRNewswire/ -- Natural Balance Pet Foods, a leader in premium pet nutrition, has been named a winner in the 2025 Pet Innovation Awards, recognizing the most outstanding companies, services and products within the rapidly expanding pet industry. The brand earned the Cat Food Innovation of the Year award for its innovative Ultra Protein portfolio – a breakthrough in feline nutrition. Ultra Protein's innovative, nutrient-forward diet is made with protein-rich organ meats to deliver high protein levels with unbeatable taste and cat acceptance. Available in both dry kibble and wet varieties, including pâté and cuts in gravy, each recipe provides the strength, energy and premium taste cats crave in every bite. The line also includes Ultra Protein+ formulations, designed to support feline health with nutrient-dense, functional ingredients. These recipes, which build on the foundation of 40%+ protein levels of Ultra Protein, are formulated to help support immune health, digestive function, and healthy skin and coat. Ultra Protein+ recipes are available in dry kibble and wet purée pouches. "It's an honor to be recognized among thousands of nominations with the Cat Food Innovation of the Year award," said Greg Shearson, CEO of Ethos Pet Brands, parent company of Natural Balance. "At Natural Balance, we recognize that cats are natural carnivores who thrive on protein-focused diets and hold high standards in terms of taste and texture. That's why we crafted Ultra Protein and Ultra Protein+ with real organ meats to deliver both the nutrition they need and the taste they instinctively crave." Both Ultra Protein and Ultra Protein+ are cooked in the U.S. and formulated to meet the needs of modern pet parents seeking premium, purposeful nutrition. With 40% protein levels in dry formulas and ingredients like chicken liver and hearts to provide essential amino acids, the recipes are tailored to support lean muscle development, digestion, and daily energy. These new recipes are now available at Pet Supplies Plus, Amazon and Chewy, and coming soon to Petco, starting at $19.99 for dry and $1.99 for wet. For more information, visit or your nearest pet retailer location. To speak with a Natural Balance representative, contact naturalbalance@ to arrange an interview or stop by our booth at SuperZoo (Booth #3152) from Aug. 13-15 to learn more about the product line. About Natural Balance® Founded in 1989, Natural Balance® Pet Foods, Inc. is a premium pet specialty brand with a complete offering of pet foods for both dogs and cats. The Natural Balance product line comprises over 100 dog and cat food and treat varieties, including Limited Ingredient, Health Protection, Specialized Nutrition and Ultra Protein. Natural Balance delivers quality, safety-tested food in every bag. Their Feed with Confidence™ program provides comprehensive, on-demand safety testing data to help eliminate wonder or worry. Their team of Registered Veterinary Technicians is available via online chat and phone to answer questions and ease concerns. Visit for more information. View original content to download multimedia: SOURCE Natural Balance Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly
Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly

Yahoo

time10 minutes ago

  • Yahoo

Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly

Eli Lilly reported growth of 172% and 68% for weight loss drug Zepbound and type 2 diabetes (T2D) treatment Mounjaro, respectively, in Q2 2025, though ceded early advantage to Novo Nordisk in the oral glucagon-like receptor agonist (GLP-1RA) arena. Eli Lilly's two tirzepatide drugs, rival to Novo Nordisk's semaglutide, brought in a combined $8.57bn in the quarter, compared to $4.33bn in Q2 2024. Mounjaro led the growth with approximately $5.2bn, while Zepbound generated around $3.4bn. Mounjaro and Zepbound helped drive the US drugmaker's total Q2 revenue to $15.56bn, up 38% from the same period last year. In a conference call, Eli Lilly CEO David Ricks acknowledged the role the two brands played in the company's revenue, highlighting their strong sales and the company's optimism for high-growth ceilings. Eli Lilly now expects full-year revenue between $60bn and $62bn, up from its previous range of $58bn to $61bn. The raise contrasted with rival Novo Nordisk, which reduced its 2025 outlook last week based on headwinds in the GLP-1RA space. However, shares in Lilly dropped 12% after market open to $656.19 following disappointing data published on the same day for oral weight loss candidate orforglipron. The GLP-1RA arena is set for a major juncture amid the potential approval of more patient-friendly oral versions. Both Novo Nordisk and Eli Lilly are developing candidates in this market and vying for an early lead. Results at orforglipron's highest dose, taken once a day, showed a 12.4% (27.3lb) weight loss at 72 weeks. Novo Nordisk's candidate – which was submitted to the US Food and Drug Administration (FDA) for approval in May 2025 – led to a 13.6% average weight loss. However, Lilly has a strong injectable GLP-1RA foundation on which to build. The 68% growth for Mounjaro, sold in the UK and Europe under the same brand name for both diabetes and weight loss, far surpassed that for Novo Nordisk's Ozempic, which only grew 15% in Q2 compared to the same period last year. Wegovy's global sales fared more favourably, growing 75% in Q2. Wegovy, which has been on the market longer than Zepbound, generated just over $16bn more than Lilly's asset. Analysis by GlobalData still forecasts a higher sales ceiling for tirzepatide by 2031 due to the drug's improved efficacy over semaglutide. Pricing discussions with Trump Eli Lilly is part of a wider pharmaceutical industry battling pricing reforms instigated by US President Donald Trump. The administration is seeking to install a most favoured nation pricing model that would match the costs of certain prescription drugs in the country to the lower prices offered in other developed nations. Executives were coy when asked about potential discussions with Trump, with CEO Ricks saying that 'long term it makes sense to rebalance [pricing].' 'We support the administration's position that medical research costs need to be shared more equitably across developed countries,' Ricks commented. Ricks went on to explain that defects in the US pharma market shift costs to patients and increase red tape. In Pfizer's Q2 earnings call, CEO Albert Bourla said it is in 'very active discussions' around drug pricing. He also confirmed that he personally discussed the matter with Trump, following letters to 17 drugmakers – including Eli Lilly – last week calling for price cuts. "Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store